Core Insights - Sofwave Medical Ltd reported a first quarter revenue of $16.7 million, reflecting a 26% year-over-year growth, with a gross margin of 76.3% [1][8] - The company achieved a recurring revenue of $7 million, marking a 49% year-over-year increase, which now constitutes over 40% of total revenue [1][5] - Sofwave's operating loss was reported at $1 million under IFRS and $0.2 million under non-IFRS, indicating stable performance compared to the previous year [1][8] Financial Highlights - First quarter revenue reached $16.7 million, a 26% increase from $13.2 million in Q1 2024 [10] - Gross profit for the quarter was $12.7 million, up 28% year-over-year [8][10] - The company maintained a gross margin of 76.3%, slightly up from 75.2% in the same quarter last year [10] - Cash and cash equivalents stood at $20.4 million as of March 31, 2025, with cash used in the quarter amounting to $1.2 million [8] Management Commentary - CEO Louis Scafuri highlighted strong revenue growth and market leadership, attributing success to new system placements and increased procedure volumes [3] - The company achieved regulatory clearance in Japan, opening new opportunities in the APAC region [4] - The launch of the LiftHD™ body applicator generated significant market enthusiasm, reinforcing Sofwave's position in non-invasive regenerative aesthetics [4][5] Operational Highlights - Over 520,000 treatments have been conducted since the initial market approval of Sofwave's technology [9] - The company is on track to achieve operating break-even in 2025 [9] - The widespread use of GLP-1 inhibitors is driving demand for Sofwave's skin lifting and muscle toning treatments [5]